Company news

iX Biopharma Ltd. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

General Announcement: : Press Release: iX Biopharma Commences Supply of Medicinal Cannabis Wafers to Brazil

June 28, 2021

IX Biopharma is pleased to announce that it will supply its novel Wafermine sublingual ketamine wafers in a pilot study funded by Chris O’Brien Lifehouse, one of Australia’s leading comprehensive cancer hospitals in Camperdown, Sydney. The study will evaluate the efficacy, acceptability, safety and tolerability of Wafermine administered as a first-line treatment for patients with advanced cancer suffering from moderate to severe pain.

June 15, 2021

IX Biopharma Expands Wafer Production Capacity to Meet Growing Demand

June 2, 2021

IX Biopharma is pleased to announce that the United States Food and Drug Administration (US FDA) has granted the Company an orphan drug designation for treatment of patients with Complex Regional Pain Syndrome (CRPS) with ketamine.

May 18, 2021

IX Biopharma is pleased to announce that it has received positive feedback from the European Medicines Agency (EMA) in its scientific advice to the Company regarding its Phase 3 clinical development programme for Wafermine, its sublingual ketamine wafer, for registration in Europe.

November 10, 2020

IX Biopharma obtains approval and registration of Silcap for the treatment of male erectile dysfunction in Singapore

October 21, 2020

IX Biopharma obtains approval and registration of Silcap® for the treatment of male erectile dysfunction in Singapore

October 20, 2020

Decks